NCT00537602TerminatedPhase 2
Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation
Actelion1 site in 1 country6 target enrollmentStarted: November 2007Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Change in nasal potential difference (NPD) in response to isoproterenol in chloride-free buffer in the presence of amiloride
Study Overview
Brief Summary
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged 12 years and older
- •Male or female
- •Non-pregnant women who are to remain non-pregnant for 3 months after the end of the study: only women who are surgically sterile, who are in the menopause (no menstruation for at least one year) or those of childbearing potential who are using a reliable method of contraception. Reliable methods of contraception for female patients include the following:
- •Barrier type devices (e.g., female condom, diaphragm and contraceptive sponge) used ONLY in combination with a spermicide
- •Intrauterine devices
- •Oral contraceptive agent
- •Depo-Provera™ (medroxyprogesterone acetate)
- •Levonorgestrel implants Abstention, the rhythm method or contraception by the partner alone are NOT reliable methods of contraception.
- •For children, a reliable method of contraception must be considered, if appropriate.
- •Accepting for the duration of the study and for 3 months thereafter to use a condom and not to procreate a child (males only)
- •Cystic fibrosis patients homozygous for the ΔF508 mutation as confirmed by genetic test
- •Signed informed consent prior to any study-mandated procedure
Exclusion Criteria
- •Any condition prohibiting the correct measurement of the NPD such as upper respiratory tract infection
- •Acute upper respiratory tract or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of screening
- •Severe renal impairment (creatinine clearance < 30 ml/min as per Cockroft and Gault)
- •Female patients who will not undergo a pregnancy test prior to enrollment in the study
- •History of significant lactose intolerance
- •History of neuropathy
- •History of cataracts or known increased risk of cataract formation
- •Presence of clinically significant diarrhea (>3 liquid stolls per days for >7 days) without definable cause within 1 month prior to screening
- •Any known factor of disease that might interfere with treatment compliance, study conduct or interruption of the results such as drug or alcohol dependence or psychiatric disease
- •FEVI <25% of predicted normal
- •Oxygen saturation at rest <88%
- •Active or passive smoking as measured using the Smokelyzer®
- •Hypersensitivity to miglustat or any excipients
- •Planned treatment or treatment with another investigational drug or therapy (e.g., gene therapy) within 1 month prior to randomization
Arms & Interventions
A
Experimental
Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
Intervention: miglustat (Drug)
B
Placebo Comparator
Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
Intervention: placebo (Drug)
Outcomes
Primary Outcomes
Change in nasal potential difference (NPD) in response to isoproterenol in chloride-free buffer in the presence of amiloride
Time Frame: Baseline (pre-dose on day 1) to end-of-treatment (day 8)
Secondary Outcomes
- Change in baseline NPD response(Baseline to end-of-treatment)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic FibrosisCystic FibrosisNCT00970346AlgiPharma AS26
Completed
Phase 2
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D MutationCystic FibrosisNCT01161537Vertex Pharmaceuticals Incorporated13
Completed
Phase 4
Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CFVitamin D DeficiencyBone Density, LowInflammation ChronicCystic Fibrosis Pulmonary ExacerbationCystic FibrosisCystic Fibrosis in ChildrenNCT05276960Hospital Infantil de Mexico Federico Gomez40
Completed
Phase 2
Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis PatientsCystic FibrosisNCT00499837Kamada, Ltd.21
Completed
Phase 2
Repeated Application of Gene Therapy in CF PatientsCystic FibrosisNCT01621867Imperial College London130